Cardiovascular toxicity of anti-angiogenic drugs

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Anti-angiogenic targeted therapies, including monoclonal antibodies and small molecules, are crucial in solid tumor treatment.
• These therapies, targeting vascular endothelial growth factor (VEGF) and tyrosine kinases, are associated with significant cardiovascular toxicities.
• Cardiovascular side effects range from hypertension to life-threatening conditions like QT prolongation and sudden cardiac death.

Purpose of the Study:

• To review and discuss the spectrum of cardiovascular toxicities associated with anti-angiogenic targeted therapies used in cancer treatment.
• To highlight the incidence and potential reversibility of these drug-induced cardiovascular adverse events.
• To provide a comprehensive overview for clinicians managing cancer patients on these therapies.

Main Methods:

• Literature review of studies on cardiovascular toxicities of anti-angiogenic targeted therapies.
• Analysis of reported side effects such as hypertension, left ventricular systolic dysfunction, heart failure, and conduction abnormalities.
• Synthesis of information regarding the frequency and reversibility of these cardiovascular events.

Main Results:

• Hypertension is the most common cardiovascular side effect.
• QT prolongation poses the most significant life-threatening risk, potentially leading to torsade de pointe and sudden cardiac death.
• Varied incidence rates across studies indicate a need for better identification and understanding of these toxicities.

Conclusions:

• Cardiovascular toxicities are a major concern with anti-angiogenic targeted therapies.
• Further research is needed to precisely identify and manage these side effects and their reversibility.
• Awareness and monitoring are essential for safe patient management.